Preliminary study for evaluating novel biomarker in the pathogenesis of breast cancer
Not Applicable
Recruiting
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000047529
- Lead Sponsor
- Kobe City Medical Center General Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
i) In pregnant or with the possibility of pregnancy ii) Selective estrogen-receptor degrader or selective estrogen-receptor modulator are administered within 30 days of FES PET iii) Referring doctor decided inappropriate to join this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relation between the ratio of ESR1 genetic mutation and FES/FDG PET inconsistency
- Secondary Outcome Measures
Name Time Method 1. Relation between FES-PET findings and the pathological result of estrogen receptor 2. Relation between clinical outcome and ESR1 genetic mutation and FES/FDG PET inconsistency